Study Reveals Exciting Physician Growth in the Areas of Mobile, Social, and Online Access

Manhattan ResearchPhysicians show continued adoption of mobile and social media for professional purposes, as well as increasing dependency on digital resources at the point of care, according to pharmaceutical and healthcare market research company Manhattan Research's latest Taking the Pulse® study of over 2,000 U.S. physicians. The tenth version of this landmark research and strategic advisory service is focused on which technologies physicians have adopted, how they are currently using them, and how they plan to use them in the future. Taking the Pulse® v10.0 provides a rich data set with topical insights for pharma marketers, agencies, physician content and technology providers, and other parties interested in connecting with physicians.

"In 2010, the conversation has shifted away from whether physicians are online to understanding the degree to which digital content is changing the way physicians practice medicine," said Meredith Ressi, VP of research at Manhattan Research. "Professional use of smartphones and online user-generated content are no longer early adopter activities of a tech-savvy few – these types of activities are the norm for the majority of physicians today."

Key topics covered in the research include:

  • Online and Offline Professional Information Sources: Online and offline information sources used, including textbooks, journals, conferences, CME, reps, search engines, sites visited
  • Mobile Technology Adoption: Device adoption by platform (iPhone, BlackBerry, Palm, Android); professional activities conducted on the smartphone; top mobile apps and websites used
  • Online User-Generated Content: Use of physician-only communities, messageboards and blogs
  • General Access and Technology Profile: Practice technology profile; frequency of Internet use; frequency of professional activities online and offline
  • Patient Interaction and Education: Patients bringing information into office; sites recommended to patients; types of patient education sources of interest
  • Digital Health Infrastructure: Adoption of electronic medical records (EMR); electronic prescribing; impact of ARRA on decision to implement EMR system

Webinar April 29 - Register Today

Mrs. Ressi will host a complimentary webinar previewing the research topics covered in the Taking the Pulse® v10.0 study on Thursday, April 29 at 11am EST.

Register here: https://www2.gotomeeting.com/register/907415971

About Taking the Pulse®
Taking the Pulse® v10.0 is a market research and strategic advisory service focused on which technologies physicians have adopted, how they are currently using them, and how they plan to use them in the future. The study was conducted in Q1 2010 via online and offline survey methodology among a nationally representative sample of 2,033 U.S. practicing physicians. Broad physician market research can be segmented to provide insights for over twenty specialist groups. For additional product and subscription information, please visit http://www.manhattanresearch.com/ttp.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Nurses, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen Health®, Cybercitizen Health® Europe, ePharma Consumer®, and ePharma Physician®. Broad consumer and physician research is complemented by targeted analysis for over 100 consumer therapeutic segments and physician specialist segments. For more information, please visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...

Eating more plant-based foods may be linked to bet…

Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovas...